

1 **Possible antiapoptotic and neuroprotective effects of magnesium sulfate on retina in a**  
2 **preterm hypoxic-ischemic rat model**

3 **Abstract**

4 **Background/aim:** The effects of systemic magnesium sulfate (MgSO<sub>4</sub>) on retina in preterm  
5 hypoxic-ischemic (HI) rat model are not known. Our aim was to investigate the effects of  
6 MgSO<sub>4</sub> on retinal ganglion cell (RGC) count, retinal ganglion cell (RGC) apoptotic index, retinal  
7 vascular endothelial growth factor receptor-2 (VEGFR-2) and glial fibrillary acidic protein  
8 (GFAP) expressions in preterm HI rat model.

9 **Materials and methods:** Fifteen postnatal day (PND) 7 rat pups were divided into 3 groups: 1.  
10 Sham-operated group, 2. HI group and 3. MgSO<sub>4</sub>-treated HI group. The second and third groups  
11 underwent ischemia followed by exposure to hypoxia for 2 hours (Vannucci model). The first  
12 and second groups received intraperitoneal saline and the third group received intraperitoneal  
13 MgSO<sub>4</sub>. On PND 10, eyes of the pups were evaluated for RGC count, apoptotic index, VEGFR-2  
14 and GFAP expressions.

15 **Results:** In both HI and MgSO<sub>4</sub>-treated HI group, the mean total RGC counts were found to be  
16 significantly decreased. However, the mean total RGC count in the MgSO<sub>4</sub>-treated HI group was  
17 significantly higher than that of the HI group. The mean apoptotic index was found to be  
18 significantly increased in the HI group. Retinal VEGFR-2 and GFAP expressions were found to  
19 be significantly higher in the HI group.

20 **Conclusions:** Magnesium sulfate preconditioning and treatment in preterm HI rat model might  
21 diminish apoptosis, relatively preserve RGCs and reduce retinal VEGFR-2 and GFAP  
22 expressions.

1 **Keywords:** Hypoxia-ischemia, magnesium sulfate, neuroprotection, retina

## 2 **1. Introduction**

3 Neonatal hypoxic ischemic (HI) brain injury is a major cause of morbidity and lifelong  
4 disabilities. Approximately 30% of newborns suffering from hypoxia/ischemia do not survive  
5 and 20-40% of the survivors develop chronic neurological impairments [1]. Furthermore,  
6 hypoxic insult to the immature retina results in death of retinal ganglion cells (RGCs) and leads  
7 to visual impairments in the neonate [2]. The prevalence of visual impairment in children with  
8 HI injury ranges from 66 to 94%. The visual dysfunctions associated with HI brain injury include  
9 strabismus, gaze palsy, nystagmus, optic atrophy, restriction of the visual field, defective color  
10 vision and reduced grating acuity [3].

11 Several experimental models are used to mimic HI in rodents and larger species to study the  
12 different categories of injury seen in human infants [4]. Lack of both oxygen (hypoxia) and  
13 blood perfusion (ischemia) must be present for a significant period to result in brain injury  
14 comparable to that observed in humans [5]. The Vannucci model is one of the most widely used  
15 experimental paradigms to induce HI injury in rat pups, resembling HI damage to the human  
16 neonatal brain [6]. Huang et al demonstrated the first evidence of HI retinal damage at both  
17 pathological and functional levels using the Vannucci model in neonatal rats [7]. They also  
18 suggested that immature retinas are more susceptible to HI injury as compared with those of  
19 mature rats.

20 On exposure to HI insult, both cerebral vascular endothelial growth factor receptor-2 (VEGFR-2)  
21 and glial fibrillary acidic protein (GFAP) expressions are known to increase through the  
22 activation of hypoxia-inducible factor (HIF)-1 $\alpha$  and N-methyl-D-aspartate (NMDA) receptors,

1 respectively [8,9]. However, there is no study in the literature that evaluates the retinal VEGFR-2  
2 and GFAP expressions in the neonatal HI rat model.

3 Magnesium sulfate ( $MgSO_4$ ) already used in the clinical context might show prophylactic effects  
4 during pregnancy, decreasing the incidence of preterm delivery, which in turn reduces the  
5 possibility of in utero abnormalities that could lead to HI events [5]. Preclinical evidence  
6 suggests that calcium ( $Ca^{+2}$ ) influx blockage via NMDA receptor, thus reducing excitotoxic  
7 damage, is the neuroprotective mechanism attributed to  $MgSO_4$  [10]. Çetinkaya et al, by using  
8 the Vannucci model, studied the effects of  $MgSO_4$  on brains of 7-day-old neonatal rats and  
9 demonstrated that  $MgSO_4$  significantly reduced the percent infarcted brain volume and Terminal  
10 deoxynucleotidyl transferase (TdT)- mediated deoxyuridine triphosphate (dUTP) Nick-End-  
11 Labeling (TUNEL) positivity [11].

12 Until now, the effects of  $MgSO_4$  on retina in the neonatal HI rat model has not been studied. Our  
13 aim was to investigate the effects of  $MgSO_4$  on RGC count, RGC apoptotic index, retinal  
14 VEGFR-2 and GFAP expressions in the preterm HI rat model.

## 15 **2. Materials and methods**

### 16 ***2.1 Animals***

17 This study was approved by the Marmara University Animal Care and Use Committee. This  
18 study was performed in Yeditepe University, Animal Research Laboratory between June 2019  
19 and August 2019. Dated pregnant Sprague-Dawley rats were housed in individual cages in a  
20 temperature-controlled room ( $21\pm 1^\circ C$ ) with free access to laboratory chow and water. Rat pups  
21 were kept in the same light cycle (lights were on from 7:00 AM to 7:00 PM). Fluorescent lights  
22 providing a more natural light environment were used in the laboratory. The pregnant rats were

1 allowed to give birth spontaneously. The day of spontaneous vaginal delivery was considered  
2 postnatal day (PND) 1 for the pups. Offspring were reared with their dams until the initiation of  
3 the experiments on PND 7. All efforts were made to minimize pain and distress. Rat pups of  
4 either sex weighing 10-18 g were used in the study.

## 5 ***2.2 Hypoxic-ischemic injury model and magnesium sulfate treatment***

6 Fifteen PND 7 rat pups were included in the study. They were considered to have a brain  
7 maturity roughly corresponding to that of the human preterm fetal brain (32-34 week-old); that  
8 is, the cerebral cortical layering is complete, the germinal matrix is involuting and the white  
9 matter is yet to be myelinated [12]. They were divided randomly and equally into 3 groups:  
10 Sham-operated (control) group, hypoxic-ischemic (HI) group and MgSO<sub>4</sub>-treated HI group.  
11 Just before ischemia, the first and second groups received intraperitoneal (IP) sterile saline (0.1  
12 ml) and the third group received IP 15% MgSO<sub>4</sub> (OnPharma, Turkey) (275 mg/kg). The dose of  
13 MgSO<sub>4</sub> used in this study was the same as that used in a previous experimental model of  
14 perinatal HI brain injury [11]. This dose was slightly higher than those used in previous  
15 experimental and clinical studies [13-15]. We preferred to use 275 mg/kg/dose of MgSO<sub>4</sub> with  
16 the intent of conferring better possible neuroprotection. Magnesium sulfate was chosen in that it  
17 might provide preconditioning and neuroprotection at the initial stage of HI. A schematic  
18 diagram of the experimental protocol is shown in Figure 1.

19 To induce HI injury, the Vannucci model was used as previously reported [16]. Animals were  
20 anesthetized lightly with inhaled isoflurane (Abbott, Germany). Surgery was performed by two  
21 investigators (SE, SI). Under operation microscope (OMS-90 Oakland, NJ), following  
22 longitudinal neck incision, the right common carotid artery of the animal was exposed, isolated

1 from the nerve and vein and sectioned between a double ligature with 5-0 surgical silk. In the  
2 sham-operated group, the right common carotid artery was only exposed. Animals exhibiting  
3 respiratory arrest due to anesthesia or bleeding during surgery were excluded. All the procedures  
4 were performed at room temperature and the total time of surgery never exceeded 3 min. After  
5 the closure of the neck incision, pups were allowed to recover for 15 min and returned to their  
6 dams for a 2 h recuperation period before HI. The animals other than the sham group were then  
7 placed into a chamber partially submerged in 37°C water to maintain a constant thermal  
8 environment and exposed to hypoxia with a warm humidified 8/92% oxygen/nitrogen mixture  
9 for 2 h.

10 Just after the completion of HI, the second doses of MgSO<sub>4</sub> and sterile saline were administered  
11 intraperitoneally to the MgSO<sub>4</sub>-treated HI group and the HI group, respectively. Following  
12 injections, the pups were returned to their cages and allowed to recover for 72 h with their dams.  
13 The third dose (24 h after the second dose) was repeated at PND 8 (Figure 1). Sham group also  
14 received the second and third doses of IP sterile saline at the same time as other groups.

### 15 ***2.3 Sacrifice, cardiac perfusion and tissue processing***

16 At PND 10, the rat pups were deeply anesthetized with ketamine (Richter Pharma Ag, Austria)  
17 and xylazine (Bayer, Germany) intraperitoneally. Transcardiac perfusion was performed by  
18 another investigator (AC). The right eyes of the pups were enucleated and embedded in paraffin  
19 wax. Lenses were gently extracted and then the eyes were serially sectioned.

### 20 ***2.4 Estimation of the total number of retinal ganglion cells***

21 Cell counting was performed by an investigator (UU) blinded to the study groups. To estimate  
22 the total RGC count, the optical fractionator technique was used [17]. For quantification of

1 RGCs, the Stereo Investigator version 11.0 (Micro Bright Field, Colchester VT, USA) was used  
2 on a PC system connected to a light microscope (Leica DM 4000B, Wetzlar, Germany). By  
3 sampling a subset of the total number of ganglion cell nuclei within the thickness of the retinal  
4 tissue and extrapolating, estimates are generated for the total number of RGCs in the entire eye,  
5 as described by West et al [18].

### 6 ***2.5 TUNEL assay and apoptotic index***

7 An in situ cell death detection Peroxidase (POD) kit (Roche Diagnostics, Mannheim, Germany)  
8 was used for the TUNEL technique and the sections were stained according to the  
9 manufacturer's protocol. In each sampling frame, a counting area was designated without bias  
10 and the apoptotic index was calculated by dividing the apoptotic (TUNEL-positive) RGC  
11 number by the total RGC number [19]. TUNEL-positive RGCs were counted by the same  
12 investigator (UU) blinded to the group assignment.

### 13 ***2.6 Immunohistochemical staining and H scoring for vascular endothelial growth factor*** 14 ***receptor-2 and glial fibrillary acidic protein***

15 Monoclonal VEGFR-2- specific antibody (Cell signaling, Danvers, MA, USA) and GFAP  
16 antibody (Abcam, ab7260, Cambridge, UK) were used for immunohistochemical staining.  
17 Immunohistochemical labeling was scored incorporating both the intensity and the distribution  
18 of specific staining. H score was derived according to the modification of the previously reported  
19 method [20]. It was performed by a single investigator (UU) blinded to the study groups.

### 20 ***2.7 Statistical analysis***

1 Statistical analyses were performed using the SPSS software version 21.0 (SPSS Inc., Chicago,  
2 IL, USA). The variables were investigated using visual (histograms, probability plots) and  
3 analytical methods (Shapiro-Wilk's test) to determine whether or not they are normally  
4 distributed. Since the variables are normally distributed, descriptive analyses were presented  
5 using mean and standard deviation (SD). One-way ANOVA was used to compare total RGC  
6 count, RGC apoptotic index and H scores of VEGFR-2 and GFAP staining between sham-  
7 operated, HI and MgSO<sub>4</sub>-treated HI groups. Levene test was used to assess the homogeneity of  
8 the variances. When an overall significance was observed, pairwise posthoc tests were performed  
9 using Tukey's test. An overall p-value of less than 0.05 was considered to show a statistically  
10 significant result.

11

### 12 **3. Results**

13 Fifteen rat pups were included in the study. The weights of the rat pups were similar for all  
14 groups. Total cell counts and apoptotic indices of the RGCs of the study groups were presented  
15 in Table 1. In both HI group and MgSO<sub>4</sub>-treated HI group, the mean total RGC counts were  
16 found to be significantly decreased when compared to the sham-operated (control) group.  
17 However, the mean total RGC count in MgSO<sub>4</sub>-treated HI group was significantly higher than  
18 that of HI group. In the HI group, the mean RGC apoptotic index was found to be significantly  
19 increased when compared to sham-operated (control) and MgSO<sub>4</sub>-treated HI groups. However,  
20 apoptotic indices of MgSO<sub>4</sub>-treated HI group and sham-operated (control) group were similar.  
21 Histological retinal cross-sections for total RGC counting and TUNEL-stained apoptotic RGCs  
22 from experimental groups were presented in Figure 2a.

1 H scores as an indicator of VEGFR-2 and GFAP expressions in retinal tissue were found to be  
2 significantly higher in HI group when compared to other groups (Table 2). On the other hand, H  
3 scores for VEGFR-2 and GFAP were similar in sham-operated (control) and MgSO<sub>4</sub>-treated HI  
4 groups. As demonstrated in Figure 2b, the retinal layer in HI group had higher VEGFR-2 and  
5 GFAP staining intensity in comparison to other groups.

#### 6 **4. Discussion**

7 To our knowledge, this is the first preclinical study evaluating the effects of systemic MgSO<sub>4</sub> on  
8 developing retina after HI insult in neonatal rats. Our results demonstrate that MgSO<sub>4</sub> might  
9 exhibit significant antiapoptotic and neuroprotective effects on the retina in preterm HI rat model  
10 by reducing TUNEL-positive cell count, relatively sparing RGCs and decreasing retinal VEGFR-  
11 2 and GFAP expressions.

12 In this study, the decrease in total RGC count after HI insult in preterm rat retina could be  
13 explained by both apoptotic and necrotic RGC death. Although we did not study the necrotic  
14 RGC percentages, we observed a significantly increased mean RGC apoptotic index value in the  
15 HI group. Even though the mean total RGC count in MgSO<sub>4</sub>-treated HI group was found to be  
16 decreased when compared to the control group, the mean apoptotic indices of these two groups  
17 were similar. This could be explained by the fact that MgSO<sub>4</sub> might have a more distinct  
18 antiapoptotic effect than its antinecrotic effect on preterm rat retina exposed to HI.

19 Excess glutamate release in HI conditions causes excitotoxic damage to the RGCs through  
20 activation of glutamate (NMDA) receptors [21]. Antagonism of NMDA receptors was shown to  
21 protect against NMDA-induced retinal cell loss [22]. Magnesium, a Ca<sup>+2</sup> antagonist, is known to  
22 antagonize NMDA-mediated excitotoxicity, thereby limiting apoptosis. Magnesium is also



1 essentially and directly involved in mitochondrial membrane stabilization, another mechanism  
2 underlying its neuroprotective, antinecrotic and antiapoptotic effects [23]. Furthermore, in  
3 human and animal models, it has been shown that MgSO<sub>4</sub> increases cerebral blood flow  
4 velocities through its vasodilatory effect [24,25]. This increment in cerebral blood flow velocities  
5 might explain the protective role of MgSO<sub>4</sub> in ischemic events and hypoxic brain damage. As a  
6 limitation, we could not study the effects of systemic MgSO<sub>4</sub> treatment on cerebral blood flow in  
7 our HI rat model.

8 Hypoxia-inducible factor-1 $\alpha$  is a hypoxia sensor and one of the most predominant effects of HIF-  
9 induced transcription is the induction of VEGF and its receptors under hypoxic conditions [8].

10 We also found significantly increased retinal VEGFR-2 expression in PND 7 neonatal rats after  
11 HI insult. It is known that VEGF has different effects on different tissues. After cerebral  
12 ischemia, the VEGF expressed by microglial cells might have a neurotrophic effect, however the  
13 VEGF expressed after retinal ischemia might have a neurodegenerative effect [26,27].

14 Treatments blocking/decreasing either VEGF (anti-VEGF treatments) or VEGFR-2 expression  
15 (such as MgSO<sub>4</sub>) could be neuroprotective in the management of HI retinopathies.

16 Müller cells are responsible for the maintenance of homeostasis in the extracellular medium of  
17 the retina and protect the neurons by releasing neurotrophic factors. During retinal injury, Müller  
18 cells are well known to undergo reactive gliosis characterized by the upregulation of GFAP [28].

19 Huang et al demonstrated HI retinal damage using the Vannucci model in preterm neonatal rats  
20 and did not find prominent retinal GFAP immunoreactivity until PND 21 [7]. However, in our  
21 study, significantly increased retinal GFAP expression, as an indicator of neuronal injury, was  
22 detected as early as PND 10 in the HI group. Moreover, Burtrum et al demonstrated that  
23 excitotoxic injury stimulates GFAP expression in PND 7 rat brains [9]. Magnesium sulfate, by

1 antagonizing NMDA receptor-induced GFAP production, seems to decelerate the gliotic  
2 response of Müller cells after HI retinal injury, thereby saving time to retinal neurons for  
3 reparative processes.

4 Antenatal MgSO<sub>4</sub> is strongly recommended for pregnant women at risk of imminent preterm  
5 birth before 32 weeks of gestation for fetal neuroprotection [29]. Our experimental model was  
6 the 'preterm' HI rat model, investigating the possible prophylactic role of systemic MgSO<sub>4</sub> in  
7 preventing both perinatal HI events and retinal injury. We, therefore, administered the first dose  
8 of MgSO<sub>4</sub> just before ischemia. However, most experimental studies have failed to confirm that  
9 MgSO<sub>4</sub> is neuroprotective if given immediately before, during or after HI [30,31]. Koning et al  
10 demonstrated that via providing mitochondrial protection, MgSO<sub>4</sub> induces strong  
11 preconditioning, *i.e.* it reduces the vulnerability of the immature brain to a subsequent severe  
12 insult when administered 6 days to 12 h before the induction of HI in the PND 7 rat [32]. The  
13 MgSO<sub>4</sub> dose was 1.1 g/kg as a bolus in that study, whereas we administered 275 mg/kg/dose as  
14 three doses, the first just before ischemia and the remaining two after hypoxia. The total MgSO<sub>4</sub>  
15 dose was less (three-fourths) than that of Koning's study. As an extension of the brain, the  
16 retinas of PND 7 rats in our study were found to be relatively spared after HI insult, even though  
17 MgSO<sub>4</sub> was administered just before HI. Moreover, we, unfortunately, could not investigate the  
18 dose-dependent effect of MgSO<sub>4</sub> on retina in this preterm HI rat model. This was a limitation of  
19 our study.

20 A common hallmark in retinal ischemia models is the progressive degeneration and final  
21 neuronal loss in the ganglion cell layer (GCL) [7]. Therefore, we focussed on GCL in our study.  
22 We did not evaluate the other retinal (inner plexiform, inner nuclear, outer plexiform and outer  
23 nuclear) layers and optic nerve at the pathological level. Furthermore, we could not study HI

1 retinal damage and effects of MgSO<sub>4</sub> treatment at the functional level with electroretinography.  
2 Our results might reflect only short-term effects of MgSO<sub>4</sub> on retinas of HI rat pups. We did not  
3 study the long-term effects. Moreover, the results of this experimental study could not be applied  
4 on human beings totally. These are limitations of our study.

5 In conclusion, systemic MgSO<sub>4</sub> preconditioning and treatment in the preterm HI rat model might  
6 diminish apoptosis, relatively preserve RGCs and reduce HI-induced retinal VEGFR-2 and  
7 GFAP expressions, suggesting that it could be a therapeutic agent in attenuating the HI insult to  
8 the developing retina.

9 **Disclosure statement:** The authors report no conflict of interest.

10

11

12

13

14

15

16

17

18

19

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

**References**

1. Centers for Disease Control and Prevention (CDC). Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment--United States, 2003. *MMWR Morbidity and Mortality Weekly Report* 2004; 53 (3): 57-59.
2. Kaur C, Sivakumar V, Foulds WS, Luu CD, Ling EA. Cellular and vascular changes in the retina of neonatal rats after an acute exposure to hypoxia. *Investigative Ophthalmology and Visual Science* 2009; 50 (11): 5364-5374. doi:10.1167/iovs.09-3552.
3. Hoyt CS. Brain injury and the eye. *Eye (London)* 2007; 21 (10): 1285-1289. doi: 10.1038/sj.eye.6702849.
4. Mallard C, Vexler ZS. Modeling Ischemia in the Immature Brain: How Translational Are Animal Models? *Stroke* 2015; 46 (10): 3006-3011. doi: 10.1161/STROKEAHA.115.007776.
5. Netto CA, Sanches EF, Odorcyk F, Duran-Carabali LE, Sizonenko SV. Pregnancy as a valuable period for preventing hypoxia-ischemia brain damage. *International Journal of Developmental Neuroscience* 2018; 70: 12-24. doi: 10.1016/j.ijdevneu.2018.06.004.
6. Vannucci SJ, Hagberg H. Hypoxia-ischemia in the immature brain. *Journal of Experimental Biology* 2004; 207 (Pt 18): 3149-3154. doi: 10.1242/jeb.01064.
7. Huang HM, Huang CC, Hung PL, Chang YC. Hypoxic-ischemic retinal injury in rat pups. *Pediatric Research* 2012; 72 (3): 224-231. doi: 10.1038/pr.2012.74.

- 1 8. Marti HJ, Bernaudin M, Bellail A, Schoch H, Euler M et al. Hypoxia-induced vascular  
2 endothelial growth factor expression precedes neovascularization after cerebral ischemia.  
3 American Journal of Pathology 2000; 156 (3): 965-976. doi: 10.1016/S0002-  
4 9440(10)64964-4.
- 5 9. Burtrum D, Silverstein FS. Excitotoxic injury stimulates glial fibrillary acidic protein  
6 mRNA expression in perinatal rat brain. Experimental Neurology 1993; 121 (1): 127-  
7 132. doi: 10.1006/exnr.1993.1078.
- 8 10. Zeevalk GD, Nicklas WJ. Evidence that the loss of the voltage-dependent Mg<sup>2+</sup> block at  
9 the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of  
10 neuronal metabolism. Journal of Neurochemistry 1992; 59 (4): 1211-1220. doi:  
11 10.1111/j.1471-4159.1992.tb08430.x.
- 12 11. Çetinkaya M, Alkan T, Özyener F, Kafa İM, Kurt MA et al. Possible neuroprotective  
13 effects of magnesium sulfate and melatonin as both pre- and post-treatment in a neonatal  
14 hypoxic-ischemic rat model. Neonatology 2011; 99 (4): 302-310. doi:  
15 10.1159/000320643.
- 16 12. Vannucci RC, Vannucci SJ. Perinatal hypoxic-ischemic brain damage: evolution of an  
17 animal model. Developmental Neuroscience 2005; 27 (2-4): 81-86. doi:  
18 10.1159/000085978.
- 19 13. Türkyılmaz C, Türkyılmaz Z, Atalay Y, Söylemezoğlu F, Celasun B. Magnesium pre-  
20 treatment reduces neuronal apoptosis in newborn rats in hypoxia-ischemia. Brain  
21 Research 2002; 955 (1-2): 133-137. doi: 10.1016/s0006-8993(02)03395-4.

- 1 14. Ichiba H, Tamai H, Negishi H, Ueda T, Kim TJ et al. Kansai Magnesium Study Group.  
2 Randomized controlled trial of magnesium sulfate infusion for severe birth asphyxia.  
3 Pediatrics International 2002; 44 (5): 505-509. doi: 10.1046/j.1442-200x.2002.01610.x.
- 4 15. Sameshima H, Ikenoue T. Long-term magnesium sulfate treatment as protection against  
5 hypoxic-ischemic brain injury in seven-day-old rats. American Journal of Obstetrics and  
6 Gynecology 2001; 184 (2): 185-190. doi: 10.1067/mob.2001.108343.
- 7 16. Vannucci RC, Vannucci SJ. A model of perinatal hypoxic-ischemic brain damage.  
8 Annals of the New York Academy of Sciences 1997; 835: 234-249. doi: 10.1111/j.1749-  
9 6632.1997.tb48634.x.
- 10 17. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total  
11 number of neurons in the subdivisions of the rat hippocampus using the optical  
12 fractionator. Anatomical Record 1991; 231 (4): 482-497. doi: 10.1002/ar.1092310411.
- 13 18. West MJ. Introduction to stereology. Cold Spring Harbor Protocols 2012; 2012 (8). doi:  
14 10.1101/pdb.top070623.
- 15 19. Abueid L, Uslu Ü, Cumbul A, Velioglu Ögünç A, Ercan F et al. Inhibition of 5-  
16 lipooxygenase by zileuton in a rat model of myocardial infarction. Anatolian Journal of  
17 Cardiology 2017; 17 (4): 269-275. doi: 10.14744/AnatolJCardiol.2016.7248.
- 18 20. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS et al. Use of a monoclonal anti-  
19 estrogen receptor antibody in the immunohistochemical evaluation of human tumors.  
20 Cancer Research 1986; 46 (8 Suppl): 4244s-4248s.
- 21 21. Kaur C, Foulds WS, Ling EA. Hypoxia-ischemia and retinal ganglion cell damage.  
22 Clinical Ophthalmology 2008; 2 (4): 879-889. doi: 10.2147/opth.s3361.

- 1 22. Sakamoto K, Endo K, Suzuki T, Fujimura K, Kurauchi Y et al. P2X7 receptor  
2 antagonists protect against N-methyl-D-aspartic acid-induced neuronal injury in the rat  
3 retina. *European Journal of Pharmacology* 2015; 756: 52-58. doi:  
4 10.1016/j.ejphar.2015.03.008.
- 5 23. Golshani-Hebroni S. Mg(++) requirement for MtHK binding, and Mg(++) stabilization of  
6 mitochondrial membranes via activation of MtHK & MtCK and promotion of  
7 mitochondrial permeability transition pore closure: A hypothesis on mechanisms  
8 underlying Mg(++)'s antioxidant and cytoprotective effects. *Gene* 2016; 581 (1): 1-13.  
9 doi: 10.1016/j.gene.2015.12.046.
- 10 24. İmamoğlu EY, Gürsoy T, Karatekin G, Ovalı F. Effects of antenatal magnesium sulfate  
11 treatment on cerebral blood flow velocities in preterm neonates. *Journal of Perinatology*  
12 2014; 34 (3): 192-196. doi: 10.1038/jp.2013.182.
- 13 25. Tanaka S, Sameshima H, Ikenoue T, Sakamoto H. Magnesium sulfate exposure increases  
14 fetal blood flow redistribution to the brain during acute non-acidemic hypoxemia in  
15 goats. *Early Human Development* 2006; 82 (9): 597-602. doi:  
16 10.1016/j.earlhumdev.2005.12.006.
- 17 26. Plate KH, Beck H, Danner S, Allegrini PR, Wiessner C. Cell type specific upregulation  
18 of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct.  
19 *Journal of Neuropathology and Experimental Neurology* 1999; 58 (6): 654-666. doi:  
20 10.1097/00005072-199906000-00010.
- 21 27. Ogata N, Yamanaka R, Yamamoto C, Miyashiro M, Kimoto T et al. Expression of  
22 vascular endothelial growth factor and its receptor, KDR, following retinal ischemia-

- 1 reperfusion injury in the rat. *Current Eye Research* 1998; 17 (11): 1087-1096. doi:  
2 10.1076/ceyr.17.11.1087.5234.
- 3 28. Hirrlinger PG, Ulbricht E, Iandiev I, Reichenbach A, Pannicke T. Alterations in protein  
4 expression and membrane properties during Müller cell gliosis in a murine model of  
5 transient retinal ischemia. *Neuroscience Letters* 2010; 472 (1): 73-78. doi:  
6 10.1016/j.neulet.2010.01.062.
- 7 29. Shepherd E, Salam RA, Middleton P, Makrides M, McIntyre S et al. Antenatal and  
8 intrapartum interventions for preventing cerebral palsy: an overview of Cochrane  
9 systematic reviews. *Cochrane Database System Review* 2017; 8 (8): CD012077. doi:  
10 10.1002/14651858.CD012077.pub2.
- 11 30. Galvin KA, Oorschot DE. Postinjury magnesium sulfate treatment is not markedly  
12 neuroprotective for striatal medium spiny neurons after perinatal hypoxia/ischemia in the  
13 rat. *Pediatric Research* 1998; 44 (5): 740-745. doi: 10.1203/00006450-199811000-00017.
- 14 31. Greenwood K, Cox P, Mehmet H, Penrice J, Amess PN et al. Magnesium sulfate  
15 treatment after transient hypoxia-ischemia in the newborn piglet does not protect against  
16 cerebral damage. *Pediatric Research* 2000; 48 (3): 346-350. doi: 10.1203/00006450-  
17 200009000-00014.
- 18 32. Koning G, Leverin AL, Nair S, Schwendimann L, Ek J et al. Magnesium induces  
19 preconditioning of the neonatal brain via profound mitochondrial protection. *Journal of*  
20 *Cerebral Blood Flow and Metabolism* 2019; 39 (6): 1038-1055. doi:  
21 10.1177/0271678X17746132.

22

23



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

**Table 1.** Total retinal ganglion cell counts and retinal apoptotic indices of the experimental groups.

Groups	Sham-operated (control) (n=5)	HI (n=5)	MgSO <sub>4</sub> -treated HI(n=5)	p value
Total RGC count	240±98 *·§	158±65 *·†	218±89 §·†	*p: 0.001 †p: 0.001 §p: 0.013
Apoptotic index	0.02±0.01 <sup>δ,¶</sup>	0.30±0.02 <sup>δ,¥</sup>	0.06±0.03 <sup>¶,¥</sup>	<sup>δ</sup> p: 0.001 <sup>¶</sup> p: NS <sup>¥</sup> p: 0.001

HI: hypoxic-ischemic, MgSO<sub>4</sub>: magnesium sulfate, RGC: retinal ganglion cell. Total RGC counts were presented as mean±standard deviation. Apoptotic indices (TUNEL-positive cells/total cells) were presented as mean±standard deviation. NS: not significant. \*·<sup>δ</sup>=sham vs HI, §·<sup>¶</sup>=sham vs MgSO<sub>4</sub>, †·<sup>¥</sup>=HI vs MgSO<sub>4</sub>.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

**Table 2.** H scores of experimental groups for vascular endothelial growth factor receptor-2 and glial fibrillary acidic protein.

Groups	Sham-operated (control) <sup>*,†</sup> (n=5)	HI <sup>*,§</sup> (n=5)	MgSO <sub>4</sub> -treated HI <sup>†,§</sup> (n=5)	p value
H score for VEGFR-2	29.6±5.4	56±4.5	33.6±4.3	*p: 0.001 †p: NS §p: 0.001
H score for GFAP	27.4±4.1	56.3±2.3	31.3±4	*p: 0.001 †p: NS §p: 0.001

HI: hypoxic-ischemic, MgSO<sub>4</sub>: magnesium sulfate, VEGFR-2: vascular endothelial growth factor receptor-2, GFAP: glial fibrillary acidic protein. H scores for VEGFR-2 and GFAP were presented as mean±standard deviation. \*=sham vs HI, p: 0.001, †=sham vs MgSO<sub>4</sub>, p: NS (not significant), §=HI vs MgSO<sub>4</sub>, p: 0.001.


1

2

3

4

5 **Figures**



6

7 **Figure 1.** Experimental steps.

8

9

10

11

12

13

14


1

2

3

4

5



6


7 **Figure 2a.** Photomicrographs demonstrating retinal ganglion cells (black arrows) (Hematoxylin

8 and eosin staining, the magnification is x10) and apoptotic retinal ganglion cells (white arrow

9 heads) (TUNEL staining, the magnification is x100) of the rat pups from experimental groups:

10 Sham, HI and MgSO4.

11



1

2 **Figure 2b.** Vascular endothelial growth factor receptor-2 (VEGFR-2) and glial fibrillary acidic  
 3 protein (GFAP) staining images of the representative retinal sections of the rat pups from  
 4 experimental groups: Sham, HI and MgSO4. VEGFR-2 staining intensity was found increased in  
 5 the retina of the HI group (brownish color) (white arrow). The magnification is x20. GFAP  
 6 staining intensity was found increased in the retina ganglion cell layer of the HI group (brownish  
 7 color) (black arrow). The magnification is x100.

8

9

10

11

12